About Altor

Altor BioScience Corporation is a biopharmaceutical company engaged in the discovery, development and commercialization of high-value, targeted immunotherapeutic agents for the treatment of cancer, viral infections, inflammatory and autoimmune diseases.

Our History

Altor was formed in 2002 by Hing C. Wong, Ph.D., as a spin-off from Sunol Molecular Corporation (“Sunol”), and is backed by leading venture capital funds, including Sanderling Ventures and the Florida Growth Fund. The Company has two proprietary technology platforms: the STAR™ platform and IL-15 superagonist and scaffold technologies.